A record of what Anand Rathi Analysis said publicly, with the source. Not advice.
“Retains a 'buy' rating on Zydus Wellness with a higher 12-month target price of ₹2,995, implying a 33% upside from its September 2 close. The acquisition of Comfort Click is seen as a strategic move to broaden its global footprint in digital consumer healthcare, positioning it for over ₹5,000 crore revenue and expecting 1% and 20% EPS accretion for FY26E and FY27E respectively.”
Anand Rathi Analysis’s track record (trackable calls only): 90 graded calls · 95% CI 27–47%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹2,995, as stated.
Window: 12 months, the time frame the call states ("12-month").
The target ₹2,995 was reached on a close. Hit.
The grader’s working: R4 TARGET_CALL: entered ₹2423.8 on 2025-09-04 (next trading session's close); target ₹2995 reached at close ₹3009.5 on 2026-07-16. Window 365 days — rule H1: the quote states "12-month".
How it played out
How this is worked out- Time to target
- The target was reached on a close 211 trading sessions (315 calendar days) after the entry.
- Worst close against it
- The closing price went as far as 22.95% against the call before the target was reached, measured from the entry price. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.